護城河比較

The FY2025 10-K describes the nation's largest nuclear fleet — approximately 22 GW across 14 stations producing 68% of 2025 electric supply — running at a 94.7% capacity factor that 'has been approximately four percentage points better than the industry average annually since 2013', with NRC licences extending to 2054 and an IRA nuclear production tax credit floor from 2024.

來源：sec.gov

The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion.

來源：sec.gov

Arm's FY2026 20-F states it "maintained market share in the mobile applications processor market of greater than 99% for many years," and describes the Arm platform as "the most pervasive architecture in the world," with "more than 350 billion Arm-based chips reported as shipped cumulatively" as of March 31, 2026 — a durable, dominant position.

來源：sec.gov

The cited edge is operating cost at scale: average refuelling outages of 22 days in 2025 against industry averages of 33 and 38 days in 2024 and 2023, a capacity factor about four points above the industry every year since 2013, and 'significant economies of scale' in what the filing calls the largest US customer-facing energy platform.

來源：sec.gov

The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power."

來源：sec.gov

Per the 20-F, Arm's advantage rests on its proprietary CPU architecture (ISA), which "is essentially a common language for software developers" and "sets the foundation for a large library of compatible software," reinforced by switching costs: customers "likely would incur significant costs in switching to competitors' architecture."

來源：sec.gov

The 10-K states Constellation is 'the largest nuclear energy company in the U.S.', is 'the nation's largest energy supplier for C&I and residential power volumes' based on EEI data, and has 'over 32% of the C&I market share of direct customer business'.

來源：sec.gov

The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date."

來源：sec.gov

20-F: >99% share of the mobile applications processor market for many years and "the most pervasive architecture in the world"; principal contested arena is the fast-growing data-center CPU market, where Arm is still a challenger to x86.

來源：sec.gov

The 10-K states 'While providing customers with a competitive price is a key focus' in retail, on roughly two-year average C&I contract terms with 77% power and 84% gas renewal rates in 2025, and the nuclear fleet's downside is set by the IRA nuclear PTC 'as unit revenues decline below levels established in the IRA'; SEC-reported operating income was 13.6% of revenue in 2025.

來源：sec.gov

Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries."

來源：sec.gov

GAAP gross margin was ~98% in FY2026 ($4,799M gross profit on $4,920M revenue), up from 97% (FY2025) and 95% (FY2024), and royalty growth was driven by "an improved mix of products with higher royalty rates per chip, such as Armv9 technology" — evidence of per-chip pricing power. Caveat: the 20-F notes ASPs decline over a chip generation and royalty per chip generally falls as volume rises.

來源：sec.gov

Generator and retailer in one — the fleet is the physical supply behind the long-term carbon-free contracts it sells to large corporate buyers.

A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish.

Arm licenses the CPU architecture and core IP that sit at the foundation of nearly all mobile SoCs and a growing share of AI/cloud data-center CPUs (CSP in-house Grace/Graviton-class designs and Arm's own AGI data-center CPU), placing it upstream of much of the AI compute stack.

• Carbon-free energy products (CORe+, Hourly CFE, long-term nuclear agreements) 未知 · 深 來源：sec.gov
• Competitive retail energy supply 領先 · 中等 來源：sec.gov
• Natural gas and geothermal generation (including Calpine) 領先 · 中等 來源：sec.gov
• Nuclear generation fleet 領先 · 深 來源：sec.gov
• Wholesale power and gas marketing 未知 · 低 來源：sec.gov

• Intismeran autogene (mRNA-4157) 未知 · 中等 來源：sec.gov
• Spikevax 前三 · 中等 來源：sec.gov
• mNEXSPIKE 前三 · 中等 來源：sec.gov
• mRESVIA 挑戰者 · 中等 來源：sec.gov
• mRNA-1010 seasonal influenza vaccine 未知 · 中等 來源：sec.gov

• Automotive CPU IP (IVI / ADAS) 前三 · 中等 來源：sec.gov
• Cloud / data-center compute CPU IP 挑戰者 · 中等 來源：sec.gov
• Mobile application processor CPU IP 領先 · 深 來源：sec.gov

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →